Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04064801
Other study ID # AdanaCTYHOSP
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 15, 2020
Est. completion date August 30, 2020

Study information

Verified date April 2021
Source Adana Numune Training and Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aimed to investigate the association between RDW and in-hospital mortality in methanol poisoning.


Description:

RDW values have been found to be an independent predictor of the prognosis among patients with heart diseases, stroke,community-acquired pneumonia (CAP), pulmonary embolism, chronic obstructive pulmonary disease (COPD), septic shock, and acute pancreatitis.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date August 30, 2020
Est. primary completion date May 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: All patients aged =18 years who were admitted to emergency departments from January 2019 to January 2020 on account of acute methanol intoxication. Exclusion Criteria: Incomplete data, Malignancy, Severe anaemia, History of erythrocyte transfusion last 6 weeks -

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey Adana City Training and Research Hospital Adana

Sponsors (1)

Lead Sponsor Collaborator
Adana Numune Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hospital mortality 7 day
Primary Need for mechanical ventilation 7 day
See also
  Status Clinical Trial Phase
Recruiting NCT06173817 - The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients Phase 2/Phase 3
Completed NCT04877067 - Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation Phase 3